Detalhe da pesquisa
1.
A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease.
Blood
; 140(19): 2053-2062, 2022 11 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35576529
2.
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
Nature
; 543(7647): 733-737, 2017 03 30.
Artigo
Inglês
| MEDLINE | ID: mdl-28329763
3.
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor.
Invest New Drugs
; 37(2): 271-281, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30073466
4.
An innovative phase I study in healthy subjects to determine the mass balance, elimination, metabolism, and absolute bioavailability of mitapivat.
Clin Transl Sci
; 16(10): 2021-2032, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37596712
5.
Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.
Antimicrob Agents Chemother
; 55(5): 2113-21, 2011 May.
Artigo
Inglês
| MEDLINE | ID: mdl-21300835
6.
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
J Med Chem
; 61(18): 8120-8135, 2018 09 27.
Artigo
Inglês
| MEDLINE | ID: mdl-30137981
7.
Differential phosphorylation and dephosphorylation of beta2-adrenoceptor sites Ser262 and Ser355,356.
Br J Pharmacol
; 147(3): 249-59, 2006 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-16331289
8.
Inhibitors of phosphoinositide 3-kinase cause defects in the postendocytic sorting of beta2-adrenergic receptors.
Exp Cell Res
; 313(12): 2586-96, 2007 Jul 15.
Artigo
Inglês
| MEDLINE | ID: mdl-17553490
9.
Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression.
J Neurochem
; 98(2): 495-505, 2006 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-16749908